1
|
Zhao J, Liu L, Lv S, Wang C, Yue H, Zhang Z. PFN1 Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass. Pharmgenomics Pers Med 2022; 14:1669-1678. [PMID: 34992429 PMCID: PMC8711734 DOI: 10.2147/pgpm.s344818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 12/15/2021] [Indexed: 11/23/2022] Open
Abstract
Purpose Alendronate is a widely used anti-osteoporotic drug. PFN1 gene is a newly identified early-onset Paget’s disease pathogenic gene. The purpose of this study is to study whether the genetic variations in this gene affect the clinical efficacy of alendronate in postmenopausal Chinese women with low bone mass. Patients and Methods Seven single nucleotide polymorphisms in PFN1 gene were genotyped. A total of 500 postmenopausal women with osteoporosis or osteopenia were included. All participants were treated with weekly alendronate 70 mg for 12 months. A total of 466 subjects completed the follow-up. Bone mineral density (BMD) of lumbar spine, femoral neck and total hip were measured at baseline and after treatment. Results After 12 months of treatment, the BMD of lumbar spine, femoral neck and total hip all increased significantly (all P < 0.001), with an average increase of 4.72 ± 5.31%, 2.08 ± 4.45%, and 2.42 ± 3.46%, respectively. At baseline, there were no significant differences in BMD at lumbar spine, femoral neck and total hip between different genotype groups (P > 0.05). We failed to identify any significant association between the genotypes or haplotypes of PFN1 and the BMD response to alendronate therapy. Conclusion Genetic polymorphisms of PFN1 may not be a major contributor to the therapeutic response to alendronate treatment in Chinese women with low bone mass.
Collapse
Affiliation(s)
- Jiao Zhao
- Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Disease, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China
| | - Li Liu
- Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Disease, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China
| | - Shanshan Lv
- Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Disease, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China
| | - Chun Wang
- Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Disease, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China
| | - Hua Yue
- Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Disease, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China
| | - Zhenlin Zhang
- Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Disease, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China
| |
Collapse
|
2
|
Ciubean AD, Ungur RA, Irsay L, Ciortea VM, Borda IM, Dogaru GB, Trifa AP, Vesa SC, Buzoianu AD. Polymorphisms of FDPS, LRP5, SOST and VKORC1 genes and their relation with osteoporosis in postmenopausal Romanian women. PLoS One 2019; 14:e0225776. [PMID: 31774873 PMCID: PMC6880991 DOI: 10.1371/journal.pone.0225776] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Accepted: 11/12/2019] [Indexed: 02/06/2023] Open
Abstract
OBJECTIVES This study aimed to assess the relationship between bone mineral density and genotypes of four polymorphisms in previously detected osteoporosis-candidate genes (FDPS rs2297480, LRP5 rs3736228, SOST rs1234612, VKORC1 rs9934438) in postmenopausal Romanian women with primary osteoporosis. METHODS An analytical, prospective, transversal, observational, case-control study on 364 postmenopausal Romanian women was carried out between June 2016 and August 2017 in Cluj Napoca, Romania. Clinical data and blood samples were collected from all study participants. Four polymorphisms were genotyped using TaqMan SNP Genotyping assays, run on a QuantStudio 3 real-time PCR machine. RESULTS Women with TT genotype in FDPS rs2297480 had significantly lower bone mineral density values in the lumbar spine and total hip, and the presence of the T allele was significantly associated with the osteoporosis. Women carrying the CC genotype in LRP5 rs3736228 tend to have lower bone mineral density values in the femoral neck and total hip. No significant association was found for the genotypes of SOST rs1234612 or VKORC1 rs9934438. CONCLUSIONS Our study showed a strong association between bone mineral density and polymorphisms in the FDPS gene, and a borderline association with LRP5 and SOST polymorphisms in postmenopausal Romanian women with osteoporosis. No association was found for VKORC1.
Collapse
Affiliation(s)
- Alina Deniza Ciubean
- Department of Rehabilitation, University of Medicine and Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania
| | - Rodica Ana Ungur
- Department of Rehabilitation, University of Medicine and Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania
- * E-mail: (RAU); (LI)
| | - Laszlo Irsay
- Department of Rehabilitation, University of Medicine and Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania
- * E-mail: (RAU); (LI)
| | - Viorela Mihaela Ciortea
- Department of Rehabilitation, University of Medicine and Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania
| | - Ileana Monica Borda
- Department of Rehabilitation, University of Medicine and Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania
| | - Gabriela Bombonica Dogaru
- Department of Rehabilitation, University of Medicine and Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania
| | - Adrian Pavel Trifa
- Department of Genetics, University of Medicine and Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania
| | - Stefan Cristian Vesa
- Department of Pharmacology, Toxicology and Clinical Pharmacology, University of Medicine and Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania
| | - Anca Dana Buzoianu
- Department of Pharmacology, Toxicology and Clinical Pharmacology, University of Medicine and Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania
| |
Collapse
|
3
|
CIUBEAN AD, IRSAY L, UNGUR RA, CIORTEA VM, BORDA IM, DOGARU BG, TRIFA AP, BUZOIANU AD. Genetic polymorphisms and their influence on therapeutic response to alendronate-a pilot study. BALNEO RESEARCH JOURNAL 2019. [DOI: 10.12680/balneo.2019.264] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Introduction: Osteoporosis has a strong genetic contribution, and several genes have been shown to influence bone mineral density. Variants in the human genome are considered important causes of differences in drug responses observed in clinical practice. In terms of bone mineral density, about 26–53% of patients do not respond to amino-bisphosphonate therapies, of which alendronate is the most widely used.
Material and method: The current study is prospective, observational, analytical, longitudinal and cohort type. It included 25 postmenopausal women treated with alendronate for 1 year. Bone mineral density at lumbar spine and proximal femur was measured and bone turnover markers (C-terminal telopeptide of type I collagen and procollagen 1N-terminal propeptide) were evaluated at 0 and 12 months of treatment. Six single nucleotide polymorphisms in osteoporosis-candidate genes were genotyped (FDPS rs2297480, LRP5 rs3736228, SOST rs1234612, VKORC1 rs9934438, GGPS1 rs10925503 and RANKL rs2277439). Treatment response was evaluated by percentage changes in bone mineral density and bone turnover markers.
Results: The heterozygous CT of FDPS rs2297480 showed lower increases in BMD values in the lumbar spine region and the homozygous CC of the GGPS1 rs10925503 showed lower increases in terms of BMD at the total hip region. No association was found for LRP5 rs3736228, SOST rs1234612, VKORC1 rs9934438 and RANKL rs2277439.
Conclusions: Romanian postmenopausal women with osteoporosis carrying the CT genotype of FDPS rs2297480 or the CC genotype of GGPS1 rs10925503 could have an unsatisfactory response to alendronate treatment.
Key words: osteoporosis; genetic polymorphism; alendronate; bone mineral density; bone turnover markers,
Collapse
Affiliation(s)
- Alina Deniza CIUBEAN
- 1. University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Laszlo IRSAY
- 1. University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Rodica Ana UNGUR
- 1. University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Viorela Mihaela CIORTEA
- 1. University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Ileana Monica BORDA
- 1. University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Bombonica Gabriela DOGARU
- 1. University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Adrian Pavel TRIFA
- University of Medicine and Pharmacy“ Iuliu Hațieganu”, Department of Genetics, Cluj-Napoca, Romania
| | - Anca Dana BUZOIANU
- University of Medicine and Pharmacy“ Iuliu Hațieganu”, Department of Pharmacology, Toxicology and Clinical Pharmacology, Cluj-Napoca, Romania
| |
Collapse
|
4
|
CIUBEAN AD, IRSAY L, UNGUR RA, CIORTEA VM, BORDA IM, DOGARU 1, BG, TRIFA AP, BUZOIANU AD. Association between polymorphisms in GGPS1 and RANKL genes and postmenopausal osteoporosis in Romanian women. BALNEO RESEARCH JOURNAL 2019. [DOI: 10.12680/balneo.2019.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Objectives: This study aimed to assess the relationship between bone mineral density, fragility fractures, fracture risk and polymorphisms of two osteoporosis-candidate genes (GGPS1 and RANKL) in Romanian women with postmenopausal osteoporosis.
Methods: An analytical, prospective, transversal, observational, case-control study on 364 postmenopausal women, of which 228 were previously diagnosed with osteoporosis, was carried out between June 2016 and August 2017 in Cluj Napoca, Romania. Clinical data and blood samples were collected from all study participants. Polymorphisms in GGPS1 and RANKL genes were genotyped using TaqMan SNP Genotyping assays, run on a QuantStudio 3 real-time PCR machine.
Results: The CT genotype in GGPS1 rs10925503 was associated with significant lower bone mineral density values at lumbar spine and femoral neck sites and a higher fracture risk compared to controls. No significant association was found between genotypes of RANKL rs2277439 with bone mineral density or fracture risk compared to the healthy controls.
Conclusions: Our study showed a strong association between low bone mineral density and genotype CT of GGPS1 rs10925503 polymorphisms. No association was found for RANKL rs2277439 polymorphism.
Collapse
Affiliation(s)
- Alina Deniza CIUBEAN
- University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Laszlo IRSAY
- University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Rodica Ana UNGUR
- University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Viorela Mihaela CIORTEA
- University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Ileana Monica BORDA
- University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Bombonica Gabriela DOGARU 1,
- University of Medicine and Pharmacy “ Iuliu Hațieganu”, Department of Rehabilitation Medicine, Cluj-Napoca, Romania
| | - Adrian Pavel TRIFA
- University of Medicine and Pharmacy“ Iuliu Hațieganu”, Department of Genetics, Cluj-Napoca, Romania
| | - Anca Dana BUZOIANU
- University of Medicine and Pharmacy“ Iuliu Hațieganu”, Department of Pharmacology, Toxicology and Clinical Pharmacology, Cluj-Napoca, Romania
| |
Collapse
|
5
|
Marozik P, Alekna V, Rudenko E, Tamulaitiene M, Rudenka A, Mastaviciute A, Samokhovec V, Cernovas A, Kobets K, Mosse I. Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis. PLoS One 2019; 14:e0221511. [PMID: 31437227 PMCID: PMC6705789 DOI: 10.1371/journal.pone.0221511] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 08/08/2019] [Indexed: 01/10/2023] Open
Abstract
Introduction Long-term treatment is used in patients with osteoporosis, and bisphosphonates (BPs) are the most commonly prescribed medications. However, in some patients this therapy is not effective, cause different side effects and complications. Unfortunately, at least one year is needed to identify and confirm an ineffectiveness of BPs therapy on bone mineral density (BMD). Among other factors, a response to BPs therapy may also be explained by genetic factors. The aim of this study was to analyze the influence of SOST, PTH, FGF2, FDPS, GGPS1, and LRP5 gene variants on the response to treatment with aminobisphosphonates. Materials and methods Women with postmenopausal osteoporosis were included to this study if they used aminobisphosphonates for at least 12 months. Exclusion criteria were: persistence on BPs therapy less than 80%, bone metabolic diseases, diseases deemed to affect bone metabolism, malignant tumours, using of any medications influencing BMD. The study protocol was approved by the local ethics committee. The BMD at the lumbar spine and femoral neck were measured using dual x-ray absorptiometry (GE Lunar) before and at least 12 months after treatment with BPs. According to BMD change, patients were divided in two groups–responders and non-responders to BPs terapy. Polymorphic variants in SOST, PTH, FGF2, FDPS, GGPS1, and LRP5 genes were determined using PCR analysis with TaqMan probes (Thermo Scientific). Results In total, 201 women with BPs therapy were included in the study. No statistically significant differences were observed in age, age at menopause, weight, height, BMI and baseline BMD levels between responders (122 subjects) and non-responders (79 subjects). As single markers, the SOST rs1234612 T/T (OR = 2.3; P = 0.02), PTH rs7125774 T/T (OR = 2.8, P = 0.0009), FDPS rs2297480 G/G (OR = 29.3, P = 2.2×10−7), and GGPS1 rs10925503 C/C+C/T (OR = 2.9; P = 0.003) gene variants were over-represented in non-responders group. No significant association between FGF2 rs6854081 and LRP5 rs3736228 gene variants and response to BPs treatment was observed. The carriers of T-T-G-C allelic combination (constructed from rs1234612, rs7125774, rs2297480, and rs10925503) were predisposed to negative response to BPs treatment (OR = 4.9, 95% CI 1.7–14.6, P = 0.005). The C-C-T-C combination was significantly over-represented in responders (OR = 0.1, 95% CI 0.1–0.5, P = 0.006). Conclusions Our findings highlight the importance of identified single gene variants and their allelic combinations for pharmacogenetics of BPs therapy of osteoporosis. Complex screening of these genetic markers could be used as a new strategy for personalized antiresorptive therapy.
Collapse
Affiliation(s)
- Pavel Marozik
- Laboratory of Human Genetics, Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, Minsk, Belarus
- Department of General Ecology, Biology, and Environmental Genetics, International Sakharov Environmental Institute of the Belarusian State University, Minsk, Belarus
- * E-mail:
| | | | - Ema Rudenko
- Department of Cardiology and Internal Diseases, Belarusian State Medical University, Minsk, Belarus
| | | | - Alena Rudenka
- Department of Cardiology and Rheumatology, Belarusian Medical Academy of Post-Graduate Education, Minsk, Belarus
| | | | - Volha Samokhovec
- Department of Cardiology and Rheumatology, Belarusian Medical Academy of Post-Graduate Education, Minsk, Belarus
| | | | - Katsiaryna Kobets
- Laboratory of Human Genetics, Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, Minsk, Belarus
| | - Irma Mosse
- Laboratory of Human Genetics, Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, Minsk, Belarus
- Department of General Ecology, Biology, and Environmental Genetics, International Sakharov Environmental Institute of the Belarusian State University, Minsk, Belarus
| |
Collapse
|